vadimezan
Small moleculeexperimental
Vadimezan is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression. — Wikipedia
Clinical trial activity
18 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 1995 (NCT00003697)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C- Mol. weight
- 282.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVadimezan ↗
- ChEMBLCHEMBL71263 ↗
Also known as
- 5,6-dimethyl-9-oxo-9h-xanthene-4-acetic acid
- 5,6-dimethylxanthenone-4-acetic acid
- 5,6-dimethyl xanthenone acetic acid
- 5,6-dimethylxanthenoneacetic acid
- 5,6-dimethylxanthenoneacetic acid, sodium salt
- 5,6-mexaa
- as1404
- as1404
- as1404
- as1404
- asa404
- asa404
- asa404
- asa 404
- asa-404
- dimethyloxoxanthene acetic acid
- dmxaa
- dmxaa
- dmxaa
- dmxaa
- nsc 640488
- vadimezan
- vadimezan
- vadimezan
- vadimezan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01071928 | Phase 2 | Jun 1, 2010 | Hoosier Cancer Research Network, Novartis |
| NCT01278758 | Phase 1 | Mar 1, 2010 | Novartis |
| NCT01290380 | Phase 1 | Feb 1, 2010 | Novartis |
| NCT01057342 | Phase 2 | Jan 1, 2010 | Cantonal Hospital of St. Gallen, Cantonal Hospital Winterthur, Swiss Group for Clinical Cancer Research, University of Bern |
| NCT01240642 | Phase 1 | Jan 1, 2010 | Novartis |
| NCT01031212 | Phase 1 | Jan 1, 2010 | Novartis, University of California, San Francisco |
| NCT01278849 | Phase 1 | Jan 1, 2010 | Novartis |
| NCT01299415 | Phase 1 | Aug 1, 2009 | Novartis |
| NCT01285453 | Phase 1 | Mar 1, 2009 | Novartis |
| NCT01299701 | Phase 1 | Dec 1, 2008 | Novartis |
| NCT00738387 | Phase 3 | Dec 1, 2008 | Novartis |
| NCT00674102 | Phase 1 | Apr 1, 2008 | Novartis |
| NCT00662597 | Phase 3 | Apr 1, 2008 | Novartis |
| NCT00111618 | Phase 2 | May 1, 2005 | Antisoma Research, Johns Hopkins University |
| NCT00832494 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2004 | Antisoma Research, University of Auckland |
| NCT00856336 | Phase 1 | May 1, 2003 | Antisoma Research, University of Auckland, University of Otago, Waikato Hospital |
| NCT00863733 | Phase 1 | May 1, 1996 | Cancer Research UK, University of Auckland |
| NCT00003697 | Phase 1 | Oct 1, 1995 | Inova Health System, University of Glasgow |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 12 | 10 | 3 | 2008 |
| Antisoma Research | For profit | 3 | 3 | 2 | 2003 |
| University of Auckland | Academic/Hospital | 3 | 0 | 2 | 1996 |
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 1996 |
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Cantonal Hospital Winterthur | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Inova Health System | Academic/Hospital | 1 | 0 | 1 | 1995 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Swiss Group for Clinical Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Glasgow | Academic/Hospital | 1 | 1 | 1 | 1995 |
| University of Otago | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Waikato Hospital | Academic/Hospital | 1 | 0 | 1 | 2003 |
15 organizations
Page 1 / 1